Financial Performance - The company's operating revenue for Q3 2022 was ¥63,085,811.80, representing a year-over-year increase of 14.10%[5] - Net profit attributable to shareholders decreased by 5.22% to ¥25,756,165.37 for the quarter, while the net profit excluding non-recurring gains and losses was ¥22,145,987.73, down 2.01%[5] - The basic earnings per share for the quarter were ¥0.44, a decrease of 6.38% compared to the same period last year[6] - The weighted average return on equity was 4.97%, down 0.81 percentage points year-over-year[6] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 66,646,445.75, compared to CNY 61,961,081.14 in Q3 2021, reflecting an increase of approximately 7.3%[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥623,455,920.67, an increase of 8.73% compared to the end of the previous year[6] - Total liabilities increased to ¥91,969,716.34 in the third quarter of 2022 from ¥71,984,609.68 in the same quarter of 2021, representing a rise of approximately 27.7%[21] - The total equity attributable to shareholders increased by 5.83% to ¥532,670,720.64 compared to the end of the previous year[6] - The total equity attributable to shareholders increased to ¥532,670,720.64 from ¥503,322,688.90, representing a growth of about 5.8%[21] Cash Flow - Cash flow from operating activities for the year-to-date was ¥74,932,246.33, reflecting a growth of 9.98%[6] - The net cash flow from operating activities for the first nine months of 2022 was CNY 74,932,246.33, up from CNY 68,132,297.09 in the same period of 2021, indicating a growth of about 12.9%[29] - The cash inflow from operating activities totaled CNY 210,741,748.56 in Q3 2022, compared to CNY 188,256,785.37 in Q3 2021, representing an increase of approximately 11.9%[29] - The company's cash and cash equivalents increased to ¥395,643,085.22 in the third quarter of 2022, up from ¥375,769,177.70 in the previous quarter, showing a growth of about 5.1%[20] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 250,652,931.07, compared to CNY 158,674,455.57 at the end of Q3 2021, showing an increase of about 57.8%[30] Research and Development - Research and development (R&D) expenses for the quarter amounted to ¥5,113,614.39, a significant increase of 106.72% year-over-year, reflecting higher personnel costs and new product registration expenses[11] - R&D expenses accounted for 8.11% of operating revenue, up 3.64 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥11,122,398.10, compared to ¥8,228,680.85 in the same period of 2021, indicating an increase of approximately 35.5%[24] - The company invested significantly in R&D, particularly in promoting thoracic and dental products, which impacted net profit growth[16] Revenue Breakdown - The company achieved operating revenue of 178.48 million RMB for the year-to-date period, representing an 18.16% increase year-over-year[16] - Revenue from PEEK material cranial repair products reached 107.52 million RMB, up 21.68% compared to the same period last year[16] - The revenue from titanium material cranial repair products was 54.66 million RMB, marking a 5.20% increase year-over-year[16] - The revenue from PEEK material sternal fixation systems surged to 5.77 million RMB, a remarkable 80.63% increase year-over-year[16] Investment Activities - The net cash flow from investing activities for the first nine months of 2022 was -CNY 114,685,668.05, an improvement from -CNY 185,909,376.41 in the same period of 2021[30] - The total cash inflow from investment activities in Q3 2022 was CNY 528,263,335.50, significantly higher than CNY 238,801,341.14 in Q3 2021, marking an increase of about 108.3%[29] - The total cash outflow from investment activities in Q3 2022 was CNY 642,949,003.55, compared to CNY 424,710,717.55 in Q3 2021, reflecting an increase of approximately 51.5%[30] - The company received CNY 526,000,000.00 from other investment-related cash activities in Q3 2022, compared to CNY 238,000,000.00 in Q3 2021, indicating a growth of about 105.8%[29] Inventory and Accounts Payable - The company’s inventory stood at approximately 38.62 million RMB as of September 30, 2022[18] - The company reported a decrease in accounts payable from ¥15,026,911.27 in the previous quarter to ¥10,666,174.28 in the current quarter, a reduction of about 29.5%[20] - Deferred income tax assets decreased to ¥2,890,438.58 from ¥3,161,943.61, reflecting a decline of approximately 8.5%[20]
康拓医疗(688314) - 2022 Q3 - 季度财报